切换至 "中华医学电子期刊资源库"

中华产科急救电子杂志 ›› 2024, Vol. 13 ›› Issue (01) : 24 -28. doi: 10.3877/cma.j.issn.2095-3259.2024.01.005

妊娠合并内分泌疾病

围孕期高催乳素血症的诊治与管理
周杨1, 吕淑兰2,()   
  1. 1. 西北工业大学医院妇科,西安 710072
    2. 西安交通大学第一附属医院妇科,西安 710061
  • 收稿日期:2023-07-26 出版日期:2024-02-18
  • 通信作者: 吕淑兰
  • 基金资助:
    陕西省重点研发计划(2022SF-163)

Diagnosis and treatment of hyperprolactinemia during periconception

Yang Zhou, Shulan Lyu()   

  • Received:2023-07-26 Published:2024-02-18
  • Corresponding author: Shulan Lyu
引用本文:

周杨, 吕淑兰. 围孕期高催乳素血症的诊治与管理[J/OL]. 中华产科急救电子杂志, 2024, 13(01): 24-28.

Yang Zhou, Shulan Lyu. Diagnosis and treatment of hyperprolactinemia during periconception[J/OL]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2024, 13(01): 24-28.

高催乳素血症是临床常见的一种病理生理状态,可由多种生理、病理、药物因素引起,常常导致闭经、溢乳和不孕,多数患者经药物治疗有效并恢复生育能力。高催乳素血症患者的妊娠时机、合并垂体催乳素瘤孕期多巴胺受体激动剂使用原则及孕期监护等均是医患关注重点。本文根据不同原因所致妊娠合并高催乳素血症的诊断及孕前、孕期与产后管理分别进行阐述,以协助临床决策。

Hyperprolactinemia represents a commonly encountered pathological physiological condition in clinical practice. It should be emphasized that hyperprolactinemia is not considered a distinct disease, but rather a physiological state that can be induced by various factors including physiological, pathological, and pharmacological causes. This condition often leads to menstrual irregularities, galactorrhea, and infertility. The majority of patients respond favorably to pharmacological interventions, resulting in the restoration of their reproductive capabilities. However, healthcare providers and patients need to pay particular attention to key aspects such as determining the appropriate time of pregnancy in individuals with hyperprolactinemia, principles for using dopamine agonists (DAs) during pregnancy in those with concurrent pituitary prolactinomas, as well as monitoring during the antenatal period. This article elucidates the diagnosis and management of hyperprolactinemia combined with pregnancy due to different etiologies, addressing preconception care, antenatal management, and postnatal considerations. Its purpose is to facilitate informed clinical decision-making.

[1]
Bernard V, Young J, Binart N. Prolactin-a pleiotropic factor in health and disease[J]. Nat Rev Endocrinol201915(6):356-365.
[2]
中华医学会妇产科学分会内分泌学组. 女性高催乳素血症诊治共识[J]. 中华妇产科杂志201651(3):161-168.
[3]
Samperi I, Lithgow K, Karavitaki N. Hyperprolactinaemia[J]. J Clin Med20198(12):1-24.
[4]
Vilar L, Vilar CF, Lyra R, et al. Pitfalls in the diagnostic evaluation of hyperprolactinemia[J]. Neuroendocrinology2019109(1):7-19.
[5]
Chanson P, Maiter D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new[J]. Best Pract Res Clin Endocrinol Metab201933(2):1-22.
[6]
Auriemma RS, Pirchio R, Pivonello C, et al. Approach to the patient with prolactinoma[J]. J Clin Endocrinol Metab2023108(9):2400-2423.
[7]
Glezer A, Bronstein MD. Prolactinomas in pregnancy: considerations before conception and during pregnancy[J]. Pituitary202023(1):65-69.
[8]
Levin G, Rottenstreich A. Prolactin, prolactin disorders, and dopamine agonists during pregnancy[J]. Hormones (Athens)201918(2):137-139.
[9]
Kalsi AK, Halder A, Jain M, et al. Prevalence and reproductive manifestations of macroprolactinemia[J]. Endocrine201963(2):332-340.
[10]
Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline[J]. J Clin Endocrinol Metab201196(2):273-288.
[11]
Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma[J]. Eur J Endocrinol2015172(5):R205-213.
[12]
Ruiz-Velasco V, Tolis G. Pregnancy in hyperprolactinemic women[J]. Fertil Steril198441(6):793-805.
[13]
Lambert K, Rees K, Seed PT, et al. Macroprolactinomas and nonfunctioning pituitary adenomas and pregnancy outcomes[J]. Obstet Gynecol2017129(1):185-194.
[14]
Montejo ÁL, Arango C, Bernardo M, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics[J]. Front Neuroendocrinol201745:25-34.
[15]
Lu Z, Sun Y, Zhang Y, et al. Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis[J]. Transl Psychiatry202212(1):1-14.
[16]
Chanson P. Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists[J]. Best Pract Res Clin Endocrinol Metab202236(6):1-11.
[1] 王亚红, 蔡胜, 葛志通, 杨筱, 李建初. 颅骨骨膜窦的超声表现一例[J/OL]. 中华医学超声杂志(电子版), 2024, 21(11): 1089-1091.
[2] 李钱梅, 何冠南, 赵婧, 陈曦, 唐玉英, 马丽琼, 梁蓉, 袁桃, 李明星. 早孕期低危妊娠和高危妊娠胎盘微血流成像特征及预后分析[J/OL]. 中华医学超声杂志(电子版), 2024, 21(07): 726-732.
[3] 唐金侨, 叶宇佳, 王港, 赵彬, 马艳宁. 医学影像学检查方法在颞下颌关节紊乱病中临床应用研究进展[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 406-411.
[4] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[5] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[6] 熊鹰, 林敬莱, 白奇, 郭剑明, 王烁. 肾癌自动化病理诊断:AI离临床还有多远?[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 535-540.
[7] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[8] 郑大雯, 王健东. 胆囊癌辅助诊断研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 769-773.
[9] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[10] 王秋生. 胆道良性疾病诊疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 779-782.
[11] 李浩, 陈棋帅, 费发珠, 张宁伟, 李元东, 王硕晨, 任宾. 慢性肝病肝纤维化无创诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 863-867.
[12] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[13] 王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 677-681.
[14] 陈慧, 邹祖鹏, 周田田, 张艺丹, 张海萍. 皮肤镜对头皮红斑性皮肤病辅助鉴别诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 692-698.
[15] 胡云鹤, 周玉焯, 付瑞瑛, 于凡, 李爱东. CHS-DRG付费制度下GB1分组住院费用影响因素分析与管理策略探讨[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 568-574.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?